Form 4: Foundation Fighting Blindness Sells 1.7M Opus Genetics Shares

Foundation Fighting Blindness Retinal Degeneration Fund sold 1.7 million shares of Opus Genetics, Inc. at $4.35 per share.

Summary

• Foundation Fighting Blindness Retinal Degeneration Fund (RDF) disposed of 1,700,000 shares of Opus Genetics, Inc. (IRD) common stock.
• The transaction occurred on May 18, 2026, at a price of $4.35 per share.
• Following the sale, the reporting entity retains beneficial ownership of 3,792,171 shares.
• The filing identifies the reporting persons as directors by deputization due to board representation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while a large sale can be perceived negatively, it is a standard administrative filing for an institutional shareholder rebalancing its portfolio.

Positives

• The transaction provides liquidity to the Foundation Fighting Blindness Retinal Degeneration Fund.

Negatives

• Significant divestment of 1.7 million shares by a major stakeholder may signal a reduction in long-term commitment or portfolio rebalancing.

Risks

• Large block sales can exert downward pressure on the share price of Opus Genetics, Inc. (IRD).

Future Outlook

No specific forward-looking guidance regarding the company's operations or future stock performance was provided in this filing.

Management Comments

• The reporting persons are deemed directors by deputization due to the appointment of Adrienne Graves, PhD and Jean Bennett, MD, PhD to the issuer's board.

Industry Context

StockSavvy.ai notes that divestments by non-profit foundations or institutional stakeholders in biotech firms are often driven by internal mandate requirements or portfolio rebalancing rather than negative sentiment regarding the issuer's clinical pipeline.

Comparison to Industry Standards

• The sale of a large block of shares by an institutional insider is a standard liquidity event in the biotech sector.
• The reporting person maintains a significant remaining stake, which is common for long-term institutional partners in early-stage biotech.

Related Party Transactions

• Foundation Fighting Blindness, Inc. is the sole member of the reporting fund and may be deemed to beneficially own the securities.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the large volume of shares sold into the market.

Next Steps

• Monitor future Form 4 filings for further changes in beneficial ownership by the Foundation Fighting Blindness.

Key Dates

Recommendation

The sale of a significant block of shares by an institutional insider warrants a hold position until the market absorbs the supply and further clarity on the foundation's long-term investment strategy is provided.

Keywords

Opus Genetics, IRD, Insider Trading, Form 4, Foundation Fighting Blindness, Biotech, Equity Divestment